Articles about Aerie Pharmaceuticals, Inc.
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021 | Business Wire
Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of
Aerie Pharma slips after announcing eye disease trial failed to meet primary endpoints | Seeking Alpha
AERIE PHARMACEUTICALS, INC. NPS 2022
Aerie Pharmaceuticals Inc. Company Profile - The Business Journals
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results | Business Wire
Aerie Pharmaceuticals Enters into Lease Agreement for New Manufacturing Plant in Ireland - Pharma Advancement
Aerie Pharmaceuticals and GrayBug Announce Research Collaboration | Business Wire
Aerie Pharma (AERI) Falls on Glaucoma Eye Drop Safety Concerns - TheStreet
AERIE PHARMACEUTICALS, INC. - Aerie Pharmaceuticals, Inc. Trademark Registration
Aerie to build manufacturing facility in Ireland
Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer | Business Wire
Aerie Pharmaceuticals (AERI) Axitinib Implant (AR-14034) Overview - Slideshow (NASDAQ:AERI) | Seeking Alpha
Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals | LinkedIn
Aerie Pharmaceuticals to Merge with Global Eye-Care Company Alcon | North Carolina Biotechnology Center
Aerie Pharmaceuticals | Capital Sign Solutions
Open-angle glaucoma therapeutics market size to grow by USD 2.58 billion from 2021 to 2026; AbbVie Inc. and Aerie Pharmaceuticals Inc, among others, emerge as key vendors - Technavio
Aerie Pharma Seeks FDA Nod to Sell Ireland-based Product in US | INN
Aerie Pharmaceuticals | PPT
Aerie Pharma to use DSM polymers to develop eye drug delivery tech
AERIE PHARMACEUTICALS, INC. 2022 NPS
